The response of human decidual leukocytes to IL-2.
暂无分享,去创建一个
D. Francis | R. Wheeler | Y. W. Loke | A. King | N. Carter
[1] A. Nagler,et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. , 1991, Journal of Clinical Investigation.
[2] S. Burdach,et al. Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor. , 1991, The Journal of clinical investigation.
[3] D. Longo,et al. Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. , 1991, Journal of immunology.
[4] P. Starkey. Expression on cells of early human pregnancy decidua, of the p75, IL-2 and p145, IL-4 receptor proteins. , 1991, Immunology.
[5] T. Waldmann,et al. The interleukin-2 receptor. , 1991, The Journal of biological chemistry.
[6] T. Chisesi,et al. Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes. , 1990, Blood.
[7] A. Uchida,et al. Studies on T‐Lineage Cells in Human Decidua of First Trimester Pregnancies , 1990, American journal of reproductive immunology.
[8] S. Strom,et al. Interleukin-1β, human leukocyte antigen HLA-DRα, and transforming growth factor-β expression in endom trium, placenta, and placental membranes , 1990 .
[9] A. Meager,et al. Phenotypic and functional analysis of human CD3- decidual leucocyte clones. , 1990, Immunology.
[10] K. Sugamura,et al. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL- 2 binding , 1990, The Journal of experimental medicine.
[11] Y. W. Loke,et al. Human trophoblast and JEG choriocarcinoma cells are sensitive to lysis by IL-2-stimulated decidual NK cells. , 1990, Cellular immunology.
[12] B. Ferry,et al. Cell populations in the human early pregnancy decidua: natural killer activity and response to interleukin-2 of CD56-positive large granular lymphocytes. , 1990, Immunology.
[13] K. Sugamura,et al. Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets. , 1990, International immunology.
[14] H. Umehara,et al. The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes. , 1990, Immunology.
[15] J. Sosman,et al. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. , 1990, Cancer research.
[16] M. Caligiuri,et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.
[17] L. Lanier,et al. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo , 1990, The Journal of experimental medicine.
[18] S. Tabibzadeh. Proliferative activity of lymphoid cells in human endometrium throughout the menstrual cycle. , 1990, The Journal of clinical endocrinology and metabolism.
[19] L. Lanier,et al. Comparative studies of human FcRIII-positive and negative natural killer cells. , 1989, Journal of immunology.
[20] J. Sosman,et al. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. , 1989, Cancer research.
[21] K. Sugamura,et al. Activation of natural killer cells via the p75 interleukin 2 receptor , 1989, The Journal of experimental medicine.
[22] R. Fisher,et al. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. , 1989, Journal of immunology.
[23] H. Asao,et al. Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor , 1989, The Journal of experimental medicine.
[24] L. Gardner,et al. Immunocytochemical characterization of the unusual large granular lymphocytes in human endometrium throughout the menstrual cycle. , 1989, Human immunology.
[25] G. Janossy,et al. Cellular events during memory T-cell activation in vitro: the UCHL1 (180,000 MW) determinant is newly synthesized after mitosis. , 1989, Immunology.
[26] Y. W. Loke,et al. Early human decidual cells exhibit NK activity against the K562 cell line but not against first trimester trophoblast. , 1989, Cellular immunology.
[27] C. Morimoto,et al. Characterization of CD45 and CD45R monoclonal antibodies using transfected mouse cell lines that express individual human leukocyte common antigens. , 1988, Journal of immunology.
[28] R. Fisher,et al. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. , 1988, Cancer research.
[29] J. Bulmer,et al. Endometrial granulocytes in human decidua react with a natural-killer (NK) cell marker, NKH1. , 1987, Immunology.
[30] J. Bulmer,et al. The T-lymphocyte population in first-trimester human decidua does not express the interleukin-2 receptor. , 1986, Immunology.
[31] N. Carter,et al. CD3- Leukocytes Present in the Human Uterus During Early Placentation: Phenotypic and Morphologic Characterization of the CD56++ Population , 1991, Developmental immunology.